118 related articles for article (PubMed ID: 9268175)
1. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis.
Holmström M; Lindmarker P; Granqvist S; Johnsson H; Lockner D
Thromb Haemost; 1997 Aug; 78(2):803-7. PubMed ID: 9268175
[TBL] [Abstract][Full Text] [Related]
2. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis.
Holmström M; Aberg W; Lockner D; Paul C
Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902
[TBL] [Abstract][Full Text] [Related]
4. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
[TBL] [Abstract][Full Text] [Related]
6. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
Stricker H; Marchetti O; Haeberli A; Mombelli G
Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
[TBL] [Abstract][Full Text] [Related]
10. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
[TBL] [Abstract][Full Text] [Related]
11. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.
Partsch H; Blättler W
J Vasc Surg; 2000 Nov; 32(5):861-9. PubMed ID: 11054217
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
Lopaciuk S; Meissner AJ; Filipecki S; Zawilska K; Sowier J; Ciesielski L; Bielawiec M; Glowinski S; Czestochowska E
Thromb Haemost; 1992 Jul; 68(1):14-8. PubMed ID: 1325076
[TBL] [Abstract][Full Text] [Related]
13. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
[TBL] [Abstract][Full Text] [Related]
14. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
[TBL] [Abstract][Full Text] [Related]
15. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
[TBL] [Abstract][Full Text] [Related]
16. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
Luomanmäki K; Grankvist S; Hallert C; Jauro I; Ketola K; Kim HC; Kiviniemi H; Koskivirta H; Sörskog L; Vilkko P
J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934
[TBL] [Abstract][Full Text] [Related]
17. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
Thromb Haemost; 1991 Mar; 65(3):251-6. PubMed ID: 1646490
[TBL] [Abstract][Full Text] [Related]
18. Practicability and quality of outpatient management of acute deep venous thrombosis.
Blättler W; Kreis N; Blättler IK
J Vasc Surg; 2000 Nov; 32(5):855-60. PubMed ID: 11054216
[TBL] [Abstract][Full Text] [Related]
19. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
